Collegium Pharmaceutical(COLL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Collegium Reports Second Quarter 2024 Financial Results – Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of$ 52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2'24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2'24 Adjusted EBITDA of$ 96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3'24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurol ...